Blair, If the issue was truly PN as Moffet says and their letter claimed, perhaps they would return if he was gone. Certainly they voted with their feet and we follow them with
our ASM votes.
I certainly respect Amy Sing's credentials. She was on the team that brought Avastin through testing to release.
"Dr. Amy P. Sing, M.D., serves as Senior Director of Medical Affairs at Genomic Health, Inc. Dr. Sing served as Senior Director of Medical and Regulatory Affairs at Seattle Genetics Inc. since June 2000. Previously, Dr. Sing served as Medical Director of Seattle Genetics Inc. from January 1999 to June 2000. From 2004 to 2006, Dr. Sing led oversight of the approved breast cancer drug Avastin Investigator Sponsored Trials (IST) program at Genentech, Inc. From 2004 to 2011, Dr. Sing worked in various other leadership and research positions at Genentech, Inc. Dr. Sing also led research teams for Seattle Genetics, Inc. from 1999 to 2003. Dr. Sing served as Medical Director of Medical Affairs and Clinical Research at CellPro, Inc., a biotechnology firm from May 1997 to December 1998. She served as Independent Director of Bio-Path Holdings, Inc. from November 3, 2014 to August 10, 2017. She served as Member of Scientific Advisory Board at Bio-Path Holdings, Inc. until September 6, 2017. She was a Faculty Member at the University of Washington and the Fred Hutchinson Cancer Research Center in Pediatrics and Pediatric Hematology and Oncology from July 1994 to February 1997. She received awards from the National Cancer Institute, American Cancer Society and Stanford University. Dr. Sing trained in Pediatric Hematology and Oncology at the Fred Hutchinson Cancer Research Center and the University of Washington from July 1990 to June 1994 and in Pediatrics at the Children’s Hospital in Boston, MA from July 1987 to June 1990. She received an M.D. from Stanford University School of Medicine and a B.A. in Anthropology from Amherst College."
